ReviewJournal of endocrinological investigation2019
The epigenetic landscape in the cardiovascular complications of diabetes.
Review in Journal of endocrinological investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Transient elevation in cellular glucose uptake exacerbates pressure overload-induced cardiac hypertrophy and dysfunction.Epigenetics · 2026Article
- Targeting the Epigenetic Remodeler GCN5 Prevents Vascular Oxidative Stress and Endothelial Dysfunction in Obesity: Insights in Patients with Cardiometabolic Disease.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
- The role of protein O-GlcNAcylation in diabetic cardiomyopathy.Biochemical Society transactions · 2024Review
- The potential DNA methylation markers of cardiovascular disease in patients with type 2 diabetes.BMC medical genomics · 2023Article
- Association of nutritional glycaemic indices with global DNA methylation patterns: results from the Moli-sani cohort.Clinical epigenetics · 2022Article
- Metabolic, structural and biochemical changes in diabetes and the development of heart failure.Diabetologia · 2022Review
- How Are Epigenetic Modifications Related to Cardiovascular Disease in Older Adults?International journal of molecular sciences · 2021Review
- Old and New Biomarkers Associated with Endothelial Dysfunction in Chronic Hyperglycemia.Oxidative medicine and cellular longevity · 2021Review
- Histone methylation and vascular biology.Clinical epigenetics · 2020Review
- The vascular epigenome in patients with obesity and type 2 diabetes: opportunities for personalized therapies.Vascular biology (Bristol, England) · 2020Review
- Epigenetic Control of Mitochondrial Function in the Vasculature.Frontiers in cardiovascular medicine · 2020Review
- Cell-Based Mechanosensation, Epigenetics, and Non-Coding RNAs in Progression of Cardiac Fibrosis.International journal of molecular sciences · 2019Review
- Epigenetic Modifications in Peripheral Blood as Potential Noninvasive Biomarker of Diabetic Retinopathy.Translational vision science & technology · 2019Article
- Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease.Journal of clinical laboratory analysis · 2019Article
- Diabetes Mellitus and Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2019Review
- Programming of Vascular Dysfunction in the Intrauterine Milieu of Diabetic Pregnancies.International journal of molecular sciences · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A growing body of evidence suggests that epigenetic modifications-changes to the genome that do not involve changes in DNA sequence-may significantly derail transcriptional programs implicated in angiogenesis, oxidative stress and inflammation, thus fostering cardiovascular damage in patients with diabetes. Notably, adverse epigenetic signals acquired over the life course can be transmitted to the offspring, and may contribute to early cardiovascular phenotypes in the young generations. Hyperglycaemia and insulin resistance-key hallmarks of diabetes-induce an array of epigenetic modifications (i.e., DNA methylation, histone marks, and non-coding RNAs) which are responsible for a long-lasting impairment of vascular and cardiac function, even after intensive glycemic control. Hence, unveiling the "epigenetic landscape" in patients with diabetes may provide a post-genomic snapshot of global cardiovascular risk, and may furnish the tools to design personalized, epigenetic-based therapies to alleviate the burden of cardiovascular disease in diabetic patients. The present review aims to acquaint the scientific community with the rapidly advancing field of epigenetics and its implications in the cardiovascular complications of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.